Asker Healthcare Group AB

Asker Healthcare Group AB

ASKER.ST
Asker Healthcare Group ABSE flagStockholm Stock Exchange
82.65
SEK
-2.30
- -
31.66BMarket Cap
Asker Healthcare Group AB
ASKER.ST
(Stockholm Stock Exchange)

Recent

price

82.65

P/E

ratio

- -

div

yld

- -

ROIC.AI

2022
2023
2024
2025
FRC
30.59
35.12
39.23
43.83
Revenue per Share
1.12
0.53
0.94
1.28
Basic EPS, GAAP
2.23
2.35
2.29
1.93
Free Cash Flow per Basic Share
- -
- -
- -
- -
Dividend per Share
2.92
3.4
4.31
5.6
Book Value per Share
-8.1
-8.48
-9.28
-7.33
Tangible Book Value per Share
383
383
383
383
Basic Weighted Avg Shares
11,718
13,453
15,025
16,787
Sales/Revenue/Turnover
6.2
4.34
6.47
5.95
Operating Margin (%)
395
548
608
816
Depreciation Expense
430
203
360
492
Net Income, GAAP
22.64
33.44
32.74
22.61
Effective Tax Rate (%)
3.67
1.51
2.4
2.93
Profit Margin (%)
1,175
1,132
1,285
1,435
Working Capital
4,477
4,552
5,346
4,951
LT Debt
2,791
3,041
3,502
6,588
Total Equity
- -
4.95
7.39
7.01
Return on Invested Capital (%)
- -
6.18
7.87
8.15
Return on Capital (%)
- -
16.76
24.36
25.91
Return on Common Equity (%)

Capital Structure

FRC

in mil. unless spec.
No data availableFinancial data will appear here once available

Working Capital

FRC

in mil. unless spec.
No data availableFinancial data will appear here once available

Growth Rates

FRC

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
- -
88.12%
Free Cash Flow
- -
- -
-16.04%
Net Income, GAAP
- -
- -
36.67%
Sales/Revenue/Turnover
- -
- -
11.73%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
3,455
3,669
- -
- -
15,025
2025
3,995
3,987
4,676
- -
16,787
2026
4,521
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.17
0.29
0.28
- -
0.94
2025
0.28
0.34
0.34
- -
1.28
2026
0.5
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Business
Asker Healthcare Group AB (ASKER.ST) is a Sweden-based healthcare company that provides medical products, devices, equipment, and related solutions to caregivers, patients, hospitals, clinics, and healthcare institutions across Europe. Founded in 2018 and headquartered in Danderyd, Sweden, the group operates through more than 50 companies in 19 countries, employing over 4,500 people and generating revenues of SEK 16 billion; it focuses on improving patient outcomes, reducing total cost of care, and ensuring a sustainable value chain via its "twin engine" strategy of organic growth and acquisitions. Core offerings encompass a broad portfolio of medical supplies, consumables, and equipment distributed by subsidiaries such as OneMed (50,000 stocked products including devices, logistics, and services like Decision Support Guide and OneWound across Nordic and Baltic markets), Bosman (stoma, wound, diabetes, and urological care devices and support in the Netherlands), QRS (medical equipment and consumables for hospitals and clinics in Netherlands and Belgium), Diashop (diabetes care products via shops and online in Germany), FysioSupplies (physiotherapy products for professionals and consumers across Europe), and Evercare Medical (comprehensive medical supplies Europe-wide); additional services include 4PL logistics via OneMed Services, aesthetic equipment via Astomed, and specialized solutions like aScan's inventory management and EvivaMed's diabetes and wound care products. Recent developments include the acquisition of Novus Med Holdings Limited in 2025, a UK distributor of endoscopic surgery technologies and patient positioning systems that enhances minimally invasive surgery offerings and bolsters UK hospital partnerships with positive EBITA impact; the purchase of Health Net Connections, a British healthcare software firm, earlier that year; the November 2025 acquisition of InnoMedicus AG, a specialist in urology devices, software, and training for prostate cancer therapies generating SEK 50 million in 2024 revenue; acquisition of distribution rights for orthopedic implants in the Baltic region; and ongoing construction of a new distribution center in Gothenburg, supporting a robust pipeline targeting 10-20 annual acquisitions amid Q2 2025 net sales growth of 9% to SEK 4 billion and EBITDA margin progress toward 10%.